PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Abstract
Authors
AJ Batty GJ Thompson PA Maroudas TE Delea